Musk threatens Apple with legal action over App Store bias towards OpenAI
PHILADELPHIA—Gregory Russotti, the Chief Technology and Manufacturing Officer at Century Therapeutics , Inc. (NASDAQ:IPSC), recently executed a sale of company stock. The transaction comes as Century Therapeutics trades near its 52-week low of $0.57, having declined 87% over the past year. According to a recent SEC filing, Russotti sold 2,360 shares of Century Therapeutics’ common stock on March 10, 2025, at a price of $0.615 per share. The transaction totaled $1,451. InvestingPro analysis suggests the stock is currently undervalued.
The filing also noted that this sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). These sales were automatic and not at Russotti’s discretion. The company, with a market capitalization of $50.7 million, currently maintains a weak financial health score according to InvestingPro metrics.
In addition, Russotti acquired 120,000 RSUs on March 11, 2025, which were granted at no cost. Each RSU represents a contingent right to receive one share of the company’s common stock. These RSUs are set to vest 25% on March 11, 2026, with the remaining 75% vesting quarterly over the following three years, contingent upon his continued service with the company.
Following these transactions, Russotti holds 392,573 shares directly. Additionally, the Gregory Russotti 2021 Family Trust holds 92,773 shares indirectly.
In other recent news, Century Therapeutics has announced a partnership with Friedrich-Alexander University Erlangen-Nürnberg to conduct a Phase 1/2 trial of its cell therapy CNTY-101 for autoimmune diseases. This collaboration aims to evaluate the safety and efficacy of the therapy, targeting conditions such as systemic lupus erythematosus and lupus nephritis. In parallel, Piper Sandler has maintained an Overweight rating on Century’s stock, adjusting the price target to $4, following promising results from the Phase I CALiPSO-1 study. These results showed an 83% overall response rate in B cell lymphoma patients, with no graft-versus-host disease or dose-limiting toxicities reported.
Century Therapeutics faced a setback as Bristol-Myers Squibb (NYSE:BMY) decided to terminate their collaboration on developing therapies for acute myeloid leukemia and multiple myeloma, effective March 12, 2025. Despite this, Century maintains a strong cash position of $245 million and is reviewing its preclinical pipeline. Additionally, the company has been notified by Nasdaq about potential delisting due to its share price falling below the $1.00 minimum, with a 180-day period granted to regain compliance. Meanwhile, Clear Street initiated coverage on Century with a Buy rating and a $9 price target, highlighting the potential of its iPSC platform and Allo-Evasion technology to advance cell therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.